Advertisement

Fibromyalgia: Treating Pain in the Juvenile Patient

Abstract

Presently, evidence for the efficacy of medications for the treatment of juvenile fibromyalgia syndrome (JFMS) is limited. While there are medications approved by the US Food and Drug Administration (duloxetine, milnacipran and pregabalin) for adults with fibromyalgia syndrome, there are none for the treatment of JFMS. A variety of medications have been prescribed for the treatment of JFMS, including (but not limited to) non-opioid analgesics, opioids, anticonvulsants, antidepressants, and muscle relaxants. Psychological therapies, most prominently cognitive behavioral therapy, are the most evidenced-based treatment modalities for JFMS. A multidisciplinary approach, combining pharmacological, behavioral and exercise-based modalities is currently the standard of care for JFMS. In the future, more stringent randomized, controlled trials with longer follow-up periods are needed in order to determine the long-term efficacy and safety of medications in the treatment of JFMS. Additionally, improved recognition of JFMS will allow for better patient recruitment to permit for adequately powered study designs.

This is a preview of subscription content, log in to check access.

Access options

Buy single article

Instant unlimited access to the full article PDF.

US$ 49.95

Price includes VAT for USA

Fig. 1

References

  1. 1.

    Buskila D. Pediatric fibromyalgia. Rheum Dis Clin North Am. 2009;35:253–61.

  2. 2.

    Kashikar-Zuck S, King C, Ting TV, Arnold LM. Juvenile fibromyalgia: different from the adult chronic pain syndrome? Curr Rheumatol Rep. 2016;18:19.

  3. 3.

    Anthony KK, Schanberg LE. Assessment and management of pain syndromes and arthritis pain in children and adolescents. Rheum Dis Clin North Am. 2007;33:625–60.

  4. 4.

    Schikler KN. Is it juvenile rheumatoid arthritis or fibromyalgia? Med Clin North Am. 2000;84:967–82.

  5. 5.

    Buskila D, Press J, Gedalia A, Klein M, Neumann L, Boehm R, Sukenik S. Assessment of nonarticular tenderness and prevalence of fibromyalgia in children. J Rheumatol. 1993;20:368–70.

  6. 6.

    Clark P, Burgos-Vargas R, Medina-Palma C, Lavielle P, Marina FF. Prevalence of fibromyalgia in children: a clinical study of Mexican children. J Rheumatol. 1998;25:2009–14.

  7. 7.

    Gerloni VGM, Fantini F. Assessment of nonarticular tenderness and prevalence of primary fibromyalgia syndrome in healthy Italian schoolchildren. Arthritis Rheum. 1998;41:1405.

  8. 8.

    Sherry DD. An overview of amplified musculoskeletal pain syndromes. J Rheumatol Suppl. 2000;58:44–8.

  9. 9.

    Yunus M, Masi AT, Calabro JJ, Miller KA, Feigenbaum SL. Primary fibromyalgia (fibrositis): clinical study of 50 patients with matched normal controls. Semin Arthritis Rheum. 1981;11:151–71.

  10. 10.

    Yunus MB, Masi AT. Juvenile primary fibromyalgia syndrome. A clinical study of thirty-three patients and matched normal controls. Arthritis Rheum. 1985;28:138–45.

  11. 11.

    Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, Tugwell P, Campbell SM, Abeles M, Clark P, et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum. 1990;33:160–72.

  12. 12.

    Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, Katz RS, Mease P, Russell AS, Russell IJ, Winfield JB, Yunus MB. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res. 2010;62:600–10.

  13. 13.

    Wolfe F, Hauser W. Fibromyalgia diagnosis and diagnostic criteria. Ann Med. 2011;43:495–502.

  14. 14.

    Ting TV, Barnett K, Lynch-Jordan A, Whitacre C, Henrickson M, Kashikar-Zuck S. 2010 American College of Rheumatology adult fibromyalgia criteria for use in an adolescent female population with juvenile fibromyalgia. J Pediatr. 2016;169(181–187):e181.

  15. 15.

    Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, Hauser W, Katz RL, Mease PJ, Russell AS, Russell IJ, Walitt B. 2016 revisions to the 2010/2011 fibromyalgia diagnostic criteria. Semin Arthritis Rheum. 2016;46:319–29.

  16. 16.

    Malleson PN, al-Matar M, Petty RE. Idiopathic musculoskeletal pain syndromes in children. J Rheumatol. 1992; 19:1786–1789.

  17. 17.

    Sherry DD, McGuire T, Mellins E, Salmonson K, Wallace CA, Nepom B. Psychosomatic musculoskeletal pain in childhood: clinical and psychological analyses of 100 children. Pediatrics. 1991;88:1093–9.

  18. 18.

    Sherry DD, Brake L, Tress JL, Sherker J, Fash K, Ferry K, Weiss PF. The treatment of juvenile fibromyalgia with an intensive physical and psychosocial program. J Pediatr. 2015;167:731–7.

  19. 19.

    Hoffart CM, Wallace DP. Amplified pain syndromes in children: treatment and new insights into disease pathogenesis. Curr Opin Rheumatol. 2014;26:592–603.

  20. 20.

    Buskila D, Ablin JN. Treating juvenile fibromyalgia: cognitive-behavioral therapy, exercise and pharmacotherapy. Pain Manag. 2013;3:323–4.

  21. 21.

    Crofford LJ. Pain management in fibromyalgia. Curr Opin Rheumatol. 2008;20:246–50.

  22. 22.

    Goldenberg DL, Felson DT, Dinerman H. A randomized, controlled trial of amitriptyline and naproxen in the treatment of patients with fibromyalgia. Arthritis Rheum. 1986;29:1371–7.

  23. 23.

    Romano TJ. Fibromyalgia in children; diagnosis and treatment. W V Med J. 1991;87:112–4.

  24. 24.

    Clark S, Tindall E, Bennett RM. A double blind crossover trial of prednisone versus placebo in the treatment of fibrositis. J Rheumatol. 1985;12:980–3.

  25. 25.

    Calandre EP, Rico-Villademoros F, Slim M. An update on pharmacotherapy for the treatment of fibromyalgia. Expert Opin Pharmacother. 2015;16:1347–68.

  26. 26.

    Ablin J, Fitzcharles MA, Buskila D, Shir Y, Sommer C, Hauser W. Treatment of fibromyalgia syndrome: recommendations of recent evidence-based interdisciplinary guidelines with special emphasis on complementary and alternative therapies. Evid Based Complement Alternat Med. 2013;2013:485272.

  27. 27.

    Macfarlane GJ, Kronisch C, Dean LE, Atzeni F, Hauser W, Fluss E, Choy E, Kosek E, Amris K, Branco J, et al. EULAR revised recommendations for the management of fibromyalgia. Ann Rheum Dis. 2017;76:318–28.

  28. 28.

    Hauser W, Arnold B, Eich W, Felde E, Flugge C, Henningsen P, Herrmann M, Kollner V, Kuhn E, Nutzinger D, et al. Management of fibromyalgia syndrome—an interdisciplinary evidence-based guideline. Ger Med Sci. 2008;6:Doc14.

  29. 29.

    Fitzcharles M-A, Ste-Marie PA, Goldenberg DL, Pereira JX, Abbey S, Choinière M, Ko G, Moulin DE, Panopalis P, Proulx J, et al. 2012 Canadian guidelines for the diagnosis and management of fibromyalgia syndrome: executive summary. Pain Res Manag J Can Pain Soc. 2013;18:119–26.

  30. 30.

    Arnold LM, Schikler KN, Bateman L, Khan T, Pauer L, Bhadra-Brown P, Clair A, Chew ML, Scavone J. Safety and efficacy of pregabalin in adolescents with fibromyalgia: a randomized, double-blind, placebo-controlled trial and a 6-month open-label extension study. Pediatr Rheumatol Online J. 2016;14:46.

  31. 31.

    Arnold LM, Goldenberg DL, Stanford SB, Lalonde JK, Sandhu HS, Keck PE Jr, Welge JA, Bishop F, Stanford KE, Hess EV, et al. Gabapentin in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled, multicenter trial. Arthritis Rheum. 2007;56:1336–44.

  32. 32.

    North JM, Hong KS, Rauck RL. The effect of a novel form of extended-release gabapentin on pain and sleep in fibromyalgia subjects: an open-label pilot study. Pain Pract. 2016;16:720–9.

  33. 33.

    Hauser W, Urrutia G, Tort S, Uceyler N, Walitt B. Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia syndrome. Cochrane Database Syst Rev. 2013;1:Cd010292.

  34. 34.

    Arnold LM, Bateman L, Palmer RH, Lin Y. Preliminary experience using milnacipran in patients with juvenile fibromyalgia: lessons from a clinical trial program. Pediatr Rheumatol Online J. 2015;13:27.

  35. 35.

    Mariutto EN, Stanford SB, Kashikar-Zuck S, Welge JA, Arnold LM. An exploratory, open trial of fluoxetine treatment of juvenile fibromyalgia. J Clin Psychopharmacol. 2012;32:293–5.

  36. 36.

    Häuser W, Petzke F, Uceyler N, Sommer C.Comparative efficacy and acceptability of amitriptyline, duloxetine and milnacipran in fibromyalgia syndrome: a systematic review with meta-analysis. Rheumatology. 2011;50:532–543

  37. 37.

    Nishishinya B, Urrutia G, Walitt B, Rodriguez A, Bonfill X, Alegre C, Darko G. Amitriptyline in the treatment of fibromyalgia: a systematic review of its efficacy. Rheumatology. 2008; 47:1741–1746

  38. 38.

    Cunningham NR, Tran ST, Lynch-Jordan AM, Ting TV, Sil S, Strotman D, Noll JG, Powers SW, Arnold LM, Kashikar-Zuck S. Psychiatric disorders in young adults diagnosed with juvenile fibromyalgia in adolescence. J Rheumatol. 2015;42:2427–33.

  39. 39.

    Kashikar-Zuck S, Parkins IS, Graham TB, Lynch AM, Passo M, Johnston M, Schikler KN, Hashkes PJ, Banez G, Richards MM. Anxiety, mood, and behavioral disorders among pediatric patients with juvenile fibromyalgia syndrome. Clin J Pain. 2008;24:620–6.

  40. 40.

    Walitt B, Urrutia G, Nishishinya MB, Cantrell SE, Hauser W. Selective serotonin reuptake inhibitors for fibromyalgia syndrome. Cochrane Database Syst Rev. 2015:Cd011735.

  41. 41.

    Ngian GS, Guymer EK, Littlejohn GO. The use of opioids in fibromyalgia. Int J Rheum Dis. 2011;14:6–11.

  42. 42.

    Peng X, Robinson RL, Mease P, Kroenke K, Williams DA, Chen Y, Faries D, Wohlreich M, McCarberg B, Hann D. Long-term evaluation of opioid treatment in fibromyalgia. Clin J Pain. 2015;31:7–13.

  43. 43.

    Fitzcharles MA, Ste-Marie PA, Gamsa A, Ware MA, Shir Y. Opioid use, misuse, and abuse in patients labeled as fibromyalgia. Am J Med. 2011;124:955–60.

  44. 44.

    Robinson RL, Kroenke K, Mease P, Williams DA, Chen Y, D’Souza D, Wohlreich M, McCarberg B. Burden of illness and treatment patterns for patients with fibromyalgia. Pain Med. 2012;13:1366–76.

  45. 45.

    Scherrer JF, Svrakic DM, Freedland KE, Chrusciel T, Balasubramanian S, Bucholz KK, Lawler EV, Lustman PJ. Prescription opioid analgesics increase the risk of depression. J Gen Intern Med. 2014;29:491–9.

  46. 46.

    Aguglia A, Salvi V, Maina G, Rossetto I, Aguglia E. Fibromyalgia syndrome and depressive symptoms: comorbidity and clinical correlates. J Affect Disord. 2011;128:262–6.

  47. 47.

    Schechter NL. Pediatric pain management and opioids: the baby and the bathwater. JAMA Pediatr. 2014;168:987–8.

  48. 48.

    Bailey JE, Campagna E, Dart RC. The underrecognized toll of prescription opioid abuse on young children. Ann Emerg Med. 2009;53:419–24.

  49. 49.

    McCabe SE, West BT, Morales M, Cranford JA, Boyd CJ. Does early onset of non-medical use of prescription drugs predict subsequent prescription drug abuse and dependence? Results from a national study. Addiction. 2007;102:1920–30.

  50. 50.

    Younger J, Parkitny L, McLain D. The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain. Clin Rheumatol. 2014;33:451–9.

  51. 51.

    Younger J, Noor N, McCue R, Mackey S. Low-dose naltrexone for the treatment of fibromyalgia: findings of a small, randomized, double-blind, placebo-controlled, counterbalanced, crossover trial assessing daily pain levels. Arthritis Rheum. 2013;65:529–38.

  52. 52.

    Metyas SK, Yeter K, Solyman J, Arkfeld D. Low dose naltrexone in the treatment of fibromyalgia. Curr Rheumatol Rev. 2017. doi:10.2174/1573397113666170321120329 [Epub ahead of print].

  53. 53.

    Younger J, Mackey S. Fibromyalgia symptoms are reduced by low-dose naltrexone: a pilot study. Pain Med. 2009;10:663–72.

  54. 54.

    Carville SF, Arendt-Nielsen L, Bliddal H, Blotman F, Branco JC, Buskila D, Da Silva JA, Danneskiold-Samsoe B, Dincer F, Henriksson C, et al. EULAR evidence-based recommendations for the management of fibromyalgia syndrome. Ann Rheum Dis. 2008;67:536–41.

  55. 55.

    de Miquel CA, Campayo J, Florez MT, Arguelles JM, Tarrio EB, Montoya MG, Martin A, Salio AM, Fuentes JV, Alberch EA, de la Camara AG. Interdisciplinary consensus document for the treatment of fibromyalgia. Actas Esp Psiquiatr. 2010;38:108–20.

  56. 56.

    Cantini F, Bellandi F, Niccoli L. Di Munno O [Fluoxetin combined with cyclobenzaprine in the treatment of fibromyalgia]. Minerva Med. 1994;85:97–100.

  57. 57.

    Bennett RM, Gatter RA, Campbell SM, Andrews RP, Clark SR, Scarola JA. A comparison of cyclobenzaprine and placebo in the management of fibrositis. A double-blind controlled study. Arthritis Rheum. 1988;31:1535–42.

  58. 58.

    Quimby LG, Gratwick GM, Whitney CD, Block SR. A randomized trial of cyclobenzaprine for the treatment of fibromyalgia. J Rheumatol Suppl. 1989;19:140–3.

  59. 59.

    Reynolds WJ, Moldofsky H, Saskin P, Lue FA. The effects of cyclobenzaprine on sleep physiology and symptoms in patients with fibromyalgia. J Rheumatol. 1991;18:452–4.

  60. 60.

    Moldofsky H, Harris HW, Archambault WT, Kwong T, Lederman S. Effects of bedtime very low dose cyclobenzaprine on symptoms and sleep physiology in patients with fibromyalgia syndrome: a double-blind randomized placebo-controlled study. J Rheumatol. 2011;38:2653–63.

  61. 61.

    Fossaluzza V, De Vita S. Combined therapy with cyclobenzaprine and ibuprofen in primary fibromyalgia syndrome. Int J Clin Pharmacol Res. 1992;12:99–102.

  62. 62.

    Santandrea S, Montrone F, Sarzi-Puttini P, Boccassini L, Caruso I. A double-blind crossover study of two cyclobenzaprine regimens in primary fibromyalgia syndrome. J Int Med Res. 1993;21:74–80.

  63. 63.

    Garcia J, Simon MA, Duran M, Canceller J, Aneiros FJ. Differential efficacy of a cognitive-behavioral intervention versus pharmacological treatment in the management of fibromyalgic syndrome. Psychol Health Med. 2006;11:498–506.

  64. 64.

    Cantini F, Niccoli L, Bellandi F. Effectiveness of fluoxetine associated with cyclobenzaprine in the treatment of fibromyalgia: twelve-months-follow up results. Reumatismo. 1995;47:103–8.

  65. 65.

    Tofferi JK, Jackson JL, O’Malley PG. Treatment of fibromyalgia with cyclobenzaprine: a meta-analysis. Arthritis Rheum. 2004;51:9–13.

  66. 66.

    Patkar AA, Bilal L, Masand PS. Management of fibromyalgia. Curr Psychiatry Rep. 2003;5:218–24.

  67. 67.

    Yilmaz R, Salli A, Cingoz HT, Kucuksen S, Ugurlu H. Efficacy of vitamin D replacement therapy on patients with chronic nonspecific widespread musculoskeletal pain with vitamin D deficiency. Int J Rheum Dis. 2016;19:1255–62.

  68. 68.

    Hsiao MY, Hung CY, Chang KV, Han DS, Wang TG. Is serum hypovitaminosis D associated with chronic widespread pain including fibromyalgia? A meta-analysis of observational studies. Pain Physician. 2015;18:E877–87.

  69. 69.

    Blagojevic Z, Nikolic V, Kisic-Tepavcevic D, Terzic Supic Z, Kovacevic R, Zivkovic Z, Stevanovic D. Musculoskeletal pain and vitamin D deficiency in children: a pilot follow-up study of vitamin D therapy in musculoskeletal/orthopedic conditions. Acta Chir Orthop Traumatol Cech. 2016;83:21–6.

  70. 70.

    Rodrigo L, Blanco I, Bobes J, de Serres FJ. Clinical impact of a gluten-free diet on health-related quality of life in seven fibromyalgia syndrome patients with associated celiac disease. BMC Gastroenterol. 2013;13:157.

  71. 71.

    Rodrigo L, Blanco I, Bobes J, de Serres FJ. Remarkable prevalence of celiac disease in patients with irritable bowel syndrome plus fibromyalgia in comparison with those with isolated irritable bowel syndrome: a case-finding study. Arthritis Res Ther. 2013;15:R201.

  72. 72.

    Taubman B, Mamula P, Sherry DD. Prevalence of asymptomatic celiac disease in children with fibromyalgia: a pilot study. Pediatr Rheumatol Online J. 2011;9:11.

  73. 73.

    Nisihara R, Marques AP, Mei A, Skare T. Celiac disease and fibromyalgia: is there an association? Rev Esp Enferm Dig. 2016;108:107–8.

  74. 74.

    Slim M, Calandre EP, Garcia-Leiva JM, Rico-Villademoros F, Molina-Barea R, Rodriguez-Lopez CM, Morillas-Arques P. The effects of a gluten-free diet versus a hypocaloric diet among patients with fibromyalgia experiencing gluten sensitivity-like symptoms: a pilot, open-label randomized clinical trial. J Clin Gastroenterol. 2016. doi:10.1097/MCG.0000000000000651.

  75. 75.

    Young L, Kemper KJ. Integrative care for pediatric patients with pain. J Altern Complement Med. 2013;19:627–32.

  76. 76.

    Petter M, Chambers CT, McGrath PJ, Dick BD. The role of trait mindfulness in the pain experience of adolescents. J Pain. 2013;14:1709–18.

  77. 77.

    Grossman P, Tiefenthaler-Gilmer U, Raysz A, Kesper U. Mindfulness training as an intervention for fibromyalgia: evidence of postintervention and 3-year follow-up benefits in well-being. Psychother Psychosom. 2007;76:226–33.

  78. 78.

    Kaplan KH, Goldenberg DL, Galvin-Nadeau M. The impact of a meditation-based stress reduction program on fibromyalgia. Gen Hosp Psychiatry. 1993;15:284–9.

  79. 79.

    Jastrowski Mano KE, Salamon KS, Hainsworth KR, Anderson Khan KJ, Ladwig RJ, Davies WH, Weisman SJ. A randomized, controlled pilot study of mindfulness-based stress reduction for pediatric chronic pain. Altern Ther Health Med. 2013;19:8–14.

  80. 80.

    Kuttner L, Chambers CT, Hardial J, Israel DM, Jacobson K, Evans K. A randomized trial of yoga for adolescents with irritable bowel syndrome. Pain Res Manag. 2006;11:217–23.

  81. 81.

    Evans S, Lung KC, Seidman LC, Sternlieb B, Zeltzer LK, Tsao JC. Iyengar yoga for adolescents and young adults with irritable bowel syndrome. J Pediatr Gastroenterol Nutr. 2014;59:244–53.

  82. 82.

    Wang C, Schmid CH, Rones R, Kalish R, Yinh J, Goldenberg DL, Lee Y, McAlindon T. A randomized trial of tai chi for fibromyalgia. N Engl J Med. 2010;363:743–54.

  83. 83.

    Terhorst L, Schneider MJ, Kim KH, Goozdich LM, Stilley CS. Complementary and alternative medicine in the treatment of pain in fibromyalgia: a systematic review of randomized controlled trials. J Manipulative Physiol Ther. 2011;34:483–96.

  84. 84.

    Martin-Sanchez E, Torralba E, Diaz-Dominguez E, Barriga A, Martin JL. Efficacy of acupuncture for the treatment of fibromyalgia: systematic review and meta-analysis of randomized trials. Open Rheumatol J. 2009;3:25–9.

  85. 85.

    Baranowsky J, Klose P, Musial F, Hauser W, Dobos G, Langhorst J. Qualitative systemic review of randomized controlled trials on complementary and alternative medicine treatments in fibromyalgia. Rheumatol Int. 2009;30:1–21.

  86. 86.

    Mayhew E, Ernst E. Acupuncture for fibromyalgia–a systematic review of randomized clinical trials. Rheumatology (Oxford). 2007;46:801–4.

  87. 87.

    Holdcraft LC, Assefi N, Buchwald D. Complementary and alternative medicine in fibromyalgia and related syndromes. Best Pract Res Clin Rheumatol. 2003;17:667–83.

  88. 88.

    Deare JC, Zheng Z, Xue CC, Liu JP, Shang J, Scott SW, Littlejohn G. Acupuncture for treating fibromyalgia. Cochrane Database Syst Rev. 2013;(5):CD007070.

  89. 89.

    Langhorst J, Klose P, Musial F, Irnich D, Hauser W. Efficacy of acupuncture in fibromyalgia syndrome–a systematic review with a meta-analysis of controlled clinical trials. Rheumatology. 2010;49:778–88.

  90. 90.

    DeSantana JM, Walsh DM, Vance C, Rakel BA, Sluka KA. Effectiveness of transcutaneous electrical nerve stimulation for treatment of hyperalgesia and pain. Curr Rheumatol Rep. 2008;10:492–9.

  91. 91.

    Fagerlund AJ, Hansen OA, Aslaksen PM. Transcranial direct current stimulation as a treatment for patients with fibromyalgia: a randomized controlled trial. Pain. 2015;156:62–71.

  92. 92.

    Donald F, Esdaile JM, Kimoff JR, Fitzcharles MA. Musculoskeletal complaints and fibromyalgia in patients attending a respiratory sleep disorders clinic. J Rheumatol. 1996;23:1612–6.

  93. 93.

    Marvisi M, Balzarini L, Mancini C, Ramponi S, Marvisi C. Fibromyalgia is frequent in obstructive sleep apnea and responds to CPAP therapy. Eur J Intern Med. 2015;26:e49–50.

  94. 94.

    Germanowicz D, Lumertz MS, Martinez D, Margarites AF. Sleep disordered breathing concomitant with fibromyalgia syndrome. J Bras Pneumol. 2006;32:333–8.

  95. 95.

    Olsen MN, Sherry DD, Boyne K, McCue R, Gallagher PR, Brooks LJ. Relationship between sleep and pain in adolescents with juvenile primary fibromyalgia syndrome. Sleep. 2013;36:509–16.

  96. 96.

    Hoffart C, Fortney S, Wallace D. Sleep disruption in children with chronic pain [abstract]. Arthritis Rheum. 2016;68(suppl 10). http://acrabstracts.org/abstract/sleep-disruption-in-children-with-chronic-pain/. Accessed 5 May 2017.

  97. 97.

    Bernardy K, Fuber N, Kollner V, Hauser W. Efficacy of cognitive-behavioral therapies in fibromyalgia syndrome—a systematic review and metaanalysis of randomized controlled trials. J Rheumatol. 2010;37:1991–2005.

  98. 98.

    Glombiewski JA, Sawyer AT, Gutermann J, Koenig K, Rief W, Hofmann SG. Psychological treatments for fibromyalgia: a meta-analysis. Pain. 2010;151:280–95.

  99. 99.

    Kashikar-Zuck S, Ting TV, Arnold LM, Bean J, Powers SW, Graham TB, Passo MH, Schikler KN, Hashkes PJ, Spalding S, et al. Cognitive behavioral therapy for the treatment of juvenile fibromyalgia: a multisite, single-blind, randomized, controlled clinical trial. Arthritis Rheum. 2012;64:297–305.

  100. 100.

    Kashikar-Zuck S, Swain NF, Jones BA, Graham TB. Efficacy of cognitive-behavioral intervention for juvenile primary fibromyalgia syndrome. J Rheumatol. 2005;32:1594–602.

  101. 101.

    Sil S, Kashikar-Zuck S. Understanding why cognitive–behavioral therapy is an effective treatment for adolescents with juvenile fibromyalgia. Int J Clin Rheumtol. 2013. doi:10.2217/IJR.2213.2213.

  102. 102.

    Degotardi PJ, Klass ES, Rosenberg BS, Fox DG, Gallelli KA, Gottlieb BS. Development and evaluation of a cognitive-behavioral intervention for juvenile fibromyalgia. J Pediatr Psychol. 2006;31:714–23.

  103. 103.

    Sil S, Arnold LM, Lynch-Jordan A, Ting TV, Peugh J, Cunningham N, Powers SW, Lovell DJ, Hashkes PJ, Passo M, et al. Identifying treatment responders and predictors of improvement after cognitive-behavioral therapy for juvenile fibromyalgia. Pain. 2014;155:1206–12.

  104. 104.

    Palermo TM, Wilson AC, Peters M, Lewandowski A, Somhegyi H. Randomized controlled trial of an Internet-delivered family cognitive-behavioral therapy intervention for children and adolescents with chronic pain. Pain. 2009;146:205–13.

  105. 105.

    Stinson JN, McGrath PJ, Hodnett ED, Feldman BM, Duffy CM, Huber AM, Tucker LB, Hetherington CR, Tse SM, Spiegel LR, et al. An internet-based self-management program with telephone support for adolescents with arthritis: a pilot randomized controlled trial. J Rheumatol. 2010;37:1944–52.

  106. 106.

    Hauser W, Klose P, Langhorst J, Moradi B, Steinbach M, Schiltenwolf M, Busch A. Efficacy of different types of aerobic exercise in fibromyalgia syndrome: a systematic review and meta-analysis of randomised controlled trials. Arthritis Res Ther. 2010;12:R79.

  107. 107.

    Hooten WM, Qu W, Townsend CO, Judd JW. Effects of strength vs aerobic exercise on pain severity in adults with fibromyalgia: a randomized equivalence trial. Pain. 2012;153:915–23.

  108. 108.

    van Koulil S, Effting M, Kraaimaat FW, van Lankveld W, van Helmond T, Cats H, van Riel PL, de Jong AJ, Haverman JF, Evers AW. Cognitive-behavioural therapies and exercise programmes for patients with fibromyalgia: state of the art and future directions. Ann Rheum Dis. 2007;66:571–81.

  109. 109.

    Jones KD, Adams D, Winters-Stone K, Burckhardt CS. A comprehensive review of 46 exercise treatment studies in fibromyalgia (1988–2005). Health Qual Life Outcomes. 2006;4:67.

  110. 110.

    Sherry DD. Amplified musculoskeletal pain: treatment approach and outcomes. J Pediatr Gastroenterol Nutr. 2008;47:693–4.

  111. 111.

    Sherry DD. Physical activity levels in the treatment of juvenile fibromyalgia. Nat Rev Rheumatol. 2013;9:8–9.

  112. 112.

    Stephens S, Feldman BM, Bradley N, Schneiderman J, Wright V, Singh-Grewal D, Lefebvre A, Benseler SM, Cameron B, Laxer R, et al. Feasibility and effectiveness of an aerobic exercise program in children with fibromyalgia: results of a randomized controlled pilot trial. Arthritis Rheum. 2008;59:1399–406.

  113. 113.

    Wilson AC, Palermo TM. Physical activity and function in adolescents with chronic pain: a controlled study using actigraphy. J Pain. 2012;13:121–30.

  114. 114.

    Sil S, Thomas S, DiCesare C, Strotman D, Ting TV, Myer G, Kashikar-Zuck S. Preliminary evidence of altered biomechanics in adolescents with juvenile fibromyalgia. Arthritis Care Res. 2015;67:102–11.

  115. 115.

    Buckhardt CS, Goldenberg D, Crofford L, Gerwin R, Gowens S, Jackson K, Kugel P, McCarberg W, Rudin N, Schanberg L, Taylor AG, Taylor J, Turk D. Guideline for the management of fibromyalgia syndrome pain in adults and children. Glenview (IL): American Pain Society (APS); 2005. p. 109 (Clinical practice guideline; no. 4).

  116. 116.

    Kashikar-Zuck S, Flowers SR, Strotman D, Sil S, Ting TV, Schikler KN. Physical activity monitoring in adolescents with juvenile fibromyalgia: findings from a clinical trial of cognitive-behavioral therapy. Arthritis Care Res. 2013;65:398–405.

  117. 117.

    Kashikar-Zuck S, Ting TV. Juvenile fibromyalgia: current status of research and future developments. Nat Rev Rheumatol. 2014;10:89–96.

  118. 118.

    American Pain Society. Assessment and management of children with chronic pain. The America Pain Society: Position statement. 2012. Available at http://americanpainsociety.org/uploads/get-involved/pediatric-chronic-pain-statement.pdf.

  119. 119.

    Tesher MS. Juvenile fibromyalgia: a multidisciplinary approach to treatment. Pediatr Ann. 2015;44:e136–41.

  120. 120.

    Simons LE, Sieberg CB, Pielech M, Conroy C, Logan DE. What does it take? Comparing intensive rehabilitation to outpatient treatment for children with significant pain-related disability. J Pediatr Psychol. 2013;38:213–23.

  121. 121.

    Sherry DD, Wallace CA. Resolution of fibromyalgia with an intensive exercise program. Clin Exp Rheumatol. 1992;10:196.

  122. 122.

    Tran ST, Thomas S, DiCesare C, Pfeiffer M, Sil S, Ting TV, Williams SE, Myer GD, Kashikar-Zuck S. A pilot study of biomechanical assessment before and after an integrative training program for adolescents with juvenile fibromyalgia. Pediatr Rheumatol Online J. 2016;14:43.

  123. 123.

    Tran ST, Guite JW, Pantaleao A, Pfeiffer M, Myer GD, Sil S, Thomas SM, Ting TV, Williams SE, Edelheit B, et al. Preliminary outcomes of a cross-site cognitive-behavioral and neuromuscular integrative training intervention for juvenile fibromyalgia. Arthritis Care Res. 2017;69:413–20.

  124. 124.

    Kashikar-Zuck S, Tran ST, Barnett K, Bromberg MH, Strotman D, Sil S, Thomas SM, Joffe N, Ting TV, Williams SE, Myer GD. A qualitative examination of a new combined cognitive-behavioral and neuromuscular training intervention for juvenile fibromyalgia. Clin J Pain. 2016;32:70–81.

  125. 125.

    Kashikar-Zuck S, Cunningham N, Sil S, Bromberg MH, Lynch-Jordan AM, Strotman D, Peugh J, Noll J, Ting TV, Powers SW, et al. Long-term outcomes of adolescents with juvenile-onset fibromyalgia in early adulthood. Pediatrics. 2014;133:e592–600.

  126. 126.

    Gregoire MC, Finley GA. Drugs for chronic pain in children: a commentary on clinical practice and the absence of evidence. Pain Res Manag. 2013;18:47–50.

  127. 127.

    Kaufman EL, Tress J, Sherry DD. Trends in medicalization of children with amplified musculoskeletal pain syndrome. Pain Med. 2016;pii:pnw188.

  128. 128.

    Tian F, Guittar P, Bout-Tabaku S. Chronic pain in children seen at a rheumatology clinic: healthcare utilization patterns [abstract]. Arthritis Rheum. 2016;68(suppl 10). http://acrabstracts.org/abstract/chronic-pain-in-children-seen-at-a-rheumatology-clinic-healthcare-utilization-patterns/. Accessed 5 May 2017.

Download references

Author information

Correspondence to David D. Sherry.

Ethics declarations

Conflict of interest

SG and DDS declare they have no conflicts of interest to disclose.

Funding

Research reported in this publication was supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health under Award Number T32-AR007442 (Dr. Gmuca) and by the Snider Family (Dr. Sherry). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Ethical approval and informed consent

This study does not qualify as human subjects research; therefore, ethical approval and informed consent were not required.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Gmuca, S., Sherry, D.D. Fibromyalgia: Treating Pain in the Juvenile Patient. Pediatr Drugs 19, 325–338 (2017). https://doi.org/10.1007/s40272-017-0233-5

Download citation